Status:
COMPLETED
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between YHR1705 and YHR1706
Lead Sponsor:
Yuhan Corporation
Conditions:
Dyslipidemia
Type 2 Diabetes Mellitus
Eligibility:
MALE
19-55 years
Phase:
PHASE1
Brief Summary
This is a phase 1, open label, multiple-dose, crossover clinical trial to investigate the pharmacokinetic drug interaction between YHR1705 and YHR1706 in healty male volunteers
Detailed Description
This is an open-label, randomized, 6-sequence, 3-period crossover study. Subjects will receive multiple oral doses of YHR1705, YHR1706 or YHR1705 + YHR1706 QD for 5 consecutive days. There will be a w...
Eligibility Criteria
Inclusion
- Healthy male with body mass index(BMI) between 18.5 and 30 kg/m2
- Who has not suffered from clinically significant disease
- Provision of signed written informed consent
Exclusion
- History of and clinically significant disease
- A history of drug abuse or the presence of positive reactions to drugs that have abuse potential in urine screenings for drugs
- Administration of other investigational products within 3 months prior to the first dosing
- Volunteers considered not eligible for the clinical trial by the investigator due to reasons including laboratory test results, ECGs, or vital signs
Key Trial Info
Start Date :
August 7 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 19 2017
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT03235362
Start Date
August 7 2017
End Date
September 19 2017
Last Update
November 1 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chonbuk National University Hospital
Jeonju, South Korea